Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer

Table 6 Multivariate Cox regression analysis

	PFS			OS
	HR	95%CI	P value	HR	95%CI	P value
KRAS mutated	1.600	1.011-2.531	0.045
LOH	1.674	0.912-3.071	0.096
Fluoropyrimidine-based CT
With irinotecan	0.600	0.372-0.969	0.037	0.352	0.164-0.757	0.007
Without irinotecan	1.000			1.000
With oxaliplatin				1.000
Without oxaliplatin				2.702	1.273-5.738	0.010
TYMS 3’UTR groups			0.043			0.027
Low expression	0.432	0.198-0.946	0.036	0.366	0.162-0.827	0.016
Medium expression	0.513	0.287-0.919	0.025	0.559	0.309-1.013	0.055
High expression	1.000			1.000
Sex
Males				1.580	0.916-2.724	0.100

CT: Chemotherapy; LOH: Loss of heterozygosity; OS: Overall survival; PFS: Progression-free survival; UTR: Untranslated region.